LITHIUM CONTAINING ALUMINOSILICATE GLASSES

• US 20180147114A1
• Filed: 11/29/2017
• Published: 05/31/2018
• Est. Priority Date: 11/30/2016
• Status: Active Grant

• Current Assignee: Corning Incorporated
• Original Assignee: Corning Incorporated
• Inventors: DeMartino, Steven Edward, Lnnroth, Nadja Teresia, Ma, Lina, Schaut, Robert Anthony, Smith, Charlene Marie, Tang, Zhongzhi, Westbrook, Jamie Todd
• Granted Patent: US 10,640,415 B2
• Time in Patent Office: Days
• CPC Class Codes: A61J 1/00 Containers specially adapted for medical or pharmaceutical purposes capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00
• CPC Class Codes: C03C 14/008 the non-glass component being in molecular form
• CPC Class Codes: C03C 21/002 to perform ion-exchange between alkali ions C03C21/005 takes precedence
• CPC Class Codes: C03C 3/076 with 40% to 90% silica, by weight C03C3/045 takes precedence
• CPC Class Codes: C03C 3/078 containing an oxide of a divalent metal, e.g. an oxide of zinc
• CPC Class Codes: C03C 3/083 containing aluminium oxide or an iron compound
• CPC Class Codes: C03C 3/087 containing calcium oxide, e.g. common sheet or container glass
• CPC Class Codes: C03C 4/20 for chemical resistant glass

Abstract

A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO₂, from 4.00 mol % to 11.00 mol % Al₂O₃, from 0.10 mol % to 16.00 mol % Li₂O, from 0.10 mol % to 12.00 mol % Na₂O, from 0.00 mol % to 5.00 mol % K₂O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B₂O₃, SrO, BaO, and ZrO₂.

Claims

1. A glass pharmaceutical package having a glass composition comprising:

from greater than or equal to 68.00 mol % to less than or equal to 81.00 mol % SiO₂;

from greater than or equal to 4.00 mol % to less than or equal to 11.00 mol % Al₂O₃;

from greater than or equal to 0.10 mol % to less than or equal to 16.00 mol % Li₂O;

from greater than or equal to 0.10 mol % to less than or equal to 12.00 mol % Na₂O;

from greater than or equal to 0.00 mol % to less than or equal to 5.00 mol % K₂O;

from greater than or equal to 0.10 mol % to less than or equal to 8.00 mol % MgO;

from greater than or equal to 0.10 mol % to less than or equal to 5.00 mol % CaO;

from greater than or equal to 0.00 mol % to less than or equal to 0.20 mol % fining agent, wherein

the glass pharmaceutical package is delamination resistant, and

the glass pharmaceutical package has class 1 or class 2 chemical durability in acid, base, and water.

2. The glass pharmaceutical package according to claim 1, wherein the fining agent is selected from the group consisting of SnO₂, CeO₂, As₂O₃, Sb₂O₃, Cl⁻

, S⁻

, F⁻

, or Fe₂O₃.

3. The glass pharmaceutical package according to claim 1, wherein the fining agent is SnO₂.

4. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package is substantially free of at least one of B₂O₃, SrO, BaO, ZrO₂, and combinations thereof.

5. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package is substantially free of B₂O₃, SrO, BaO, and ZrO₂.

6. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises from greater than or equal to 1.50 mol % to less than or equal to 16.00 mol % Li₂O.

7. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises from greater than or equal to 0.10 mol % to less than or equal to 7.50 mol % MgO.

8. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a ratio of (Li+Na+K)/(Si+Al) that is from greater than or equal to 0.05 to less than or equal to 0.50.

9. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a ratio of (Li+Na+K)/(Si+Al) that is from greater than or equal to 0.05 to less than or equal to 0.15.

10. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a density from greater than or equal to 2.25 g/cm³ to less than or equal to 2.50 g/cm³.

11. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a molar volume from greater than or equal to 24.00 cm³/mol to less than or equal to 27.00 cm³/mol.

12. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package has a delamination factor less than or equal to 10.

13. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a strain point from greater than or equal to 450°

C. to less than or equal to 625°

C.

14. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises an annealing point from greater than or equal to 500°

C. to less than or equal to 675°

C.

15. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a softening point from greater than or equal to 750°

C. to less than or equal to 950°

C.

16. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a CTE from greater than or equal to 4.20 ppm/°

C. to less than or equal to 7.00 ppm/°

C.

17. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a liquidus viscosity Log from greater than or equal to 3.50 poise to less than or equal to 6.00 poise.

18. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a Young'"'"'s modulus from greater than or equal to 10.00 mpsi to less than or equal to 12.00 mpsi.

19. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a shear modulus from greater than or equal to 4.00 mpsi to less than or equal to 5.00 mpsi.

20. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm² to less than or equal to 1.5 mg/dm².

21. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm² to less than or equal to 0.7 mg/dm².

22. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm² to less than or equal to 175 mg/dm².

23. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm² to less than or equal to 75 mg/dm².

24. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μ

g/g to less than or equal to 100 μ

g/g.

25. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μ

g/g to less than or equal to 62 μ

g/g.

26. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a surface compressive stress of at least 350 MPa.

27. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a depth of compression from greater than or equal to 0.05t to less than or equal to 0.25t.

28. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a central tension from greater than or equal to 5 MPa to less than or equal to 160 MPa.

29. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package comprises a diffusivity of potassium ions at 420°

C. is from greater than or equal to 0.50 μ

m²/hr to less than or equal to 15.00 μ

m²/hr.

30. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of less than or equal to about 15.00 J/m².

31. The glass pharmaceutical package according to claim 1, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of greater than or equal to 17.00 J/m².

32. A glass pharmaceutical package having a glass composition comprising:

from greater than or equal to 68.00 mol % to less than or equal to 81.00 mol % SiO₂;

from greater than or equal to 6.10 mol % to less than or equal to 7.00 mol % Al₂O₃;

from greater than or equal to 3.10 mol % to less than or equal to 6.60 mol % Li₂O;

from greater than or equal to 1.40 mol % to less than or equal to 3.00 mol % Na₂O;

from greater than or equal to 0.00 mol % to less than or equal to 5.00 mol % K₂O;

from greater than or equal to 5.10 mol % to less than or equal to 7.50 mol % MgO;

from greater than or equal to 0.10 mol % to less than or equal to 5.00 mol % CaO;

from greater than or equal to 0.00 mol % to less than or equal to 0.20 mol % fining agent, wherein

the glass pharmaceutical package is delamination resistant,

the glass pharmaceutical package has class 1 or class 2 chemical durability in acid, base, and water, and

the glass pharmaceutical package is substantially free of B₂O₃, SrO, BaO, and ZrO₂.

33. The glass pharmaceutical package according to claim 32, wherein the fining agent is selected from the group consisting of SnO₂, CeO₂, As₂O₃, Sb₂O₃, Cl⁻

, S⁻

, F⁻

, or Fe₂O₃.

34. The glass pharmaceutical package according to claim 32, wherein the fining agent is SnO₂.

35. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a ratio of (Li+Na+K)/(Si+Al) that is greater than or equal to 0.05 to less than or equal to 0.50.

36. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package a ratio of (Li+Na+K)/(Si+Al) that is greater than or equal to 0.05 to less than or equal to 0.15.

37. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a density from greater than or equal to 2.25 g/cm³ to less than or equal to 2.50 g/cm³.

38. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a molar volume from greater than or equal to 24.00 cm³/mol to less than or equal to 27.00 cm³/mol.

39. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package has a delamination factor less than or equal to 10.

40. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a strain point from greater than or equal to 450°

C. to less than or equal to 625°

C.

41. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises an annealing point from greater than or equal to 500°

C. to less than or equal to 675°

C.

42. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a softening point from greater than or equal to 750°

C. to less than or equal to 950°

C.

43. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a CTE from greater than or equal to 4.20 ppm/°

C. to less than or equal to 7.00 ppm/°

C.

44. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a liquidus viscosity Log from greater than or equal to 3.50 poise to less than or equal to 6.00 poise.

45. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a Young'"'"'s modulus from greater than or equal to 10.00 mpsi to less than or equal to 12.00 mpsi.

46. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a shear modulus from greater than or equal to 4.00 mpsi to less than or equal to 5.00 mpsi.

47. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm² to less than or equal to 1.5 mg/dm².

48. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a chemical durability in acid as measured by DIN 12116 from greater than or equal to 0.0 mg/dm² to less than or equal to 0.7 mg/dm².

49. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm² to less than or equal to 175 mg/dm².

50. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a chemical durability in base as measured by ISO 695 from greater than or equal to 0 mg/dm² to less than or equal to 75 mg/dm².

51. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μ

g/g to less than or equal to 100 μ

g/g.

52. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a chemical durability in water as measured by ISO 720 from greater than or equal to 0 μ

g/g to less than or equal to 62 μ

g/g.

53. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a surface compressive stress of at least 350 MPa.

54. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises is strengthened by ion exchange and a depth of compression from greater than or equal to 0.05t to 0.25t.

55. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a central tension from greater than or equal to 5 MPa to less than or equal to 160 MPa.

56. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package comprises a diffusivity of potassium ions at 420°

C. is from greater than or equal to 0.50 μ

m²/hr to less than or equal to 15.00 μ

m²/hr.

57. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of less than or equal to about 15.00 J/m².

58. The glass pharmaceutical package according to claim 32, wherein the glass pharmaceutical package is strengthened by ion exchange and comprises a stored energy of greater than or equal to 17.00 J/m².